Veru Inc. to Present Innovative Research at ObesityWeek
Veru Inc. (NASDAQ: VERU), a company dedicated to developing advanced biopharmaceutical solutions for weight management and oncology, is poised to present groundbreaking research at ObesityWeek.
Details of the Upcoming Presentation
This presentation, titled "Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss," is scheduled for November 5, 2024, from 2:30 PM to 3:30 PM Central Daylight Time at the Henry B. González Convention Center. This significant event will underscore how enobosarm could enhance weight loss while preserving muscle mass.
Enobosarm: A Promising Treatment
The research centers around the Phase 2b clinical trial aimed at evaluating the effects of enobosarm, a novel selective androgen receptor modulator (SARM). This trial is focused on older patients, particularly those aged over 60, who face challenges such as sarcopenic obesity—a condition where obesity coexists with muscle loss.
Understanding Sarcopenic Obesity
Currently, about 41.5% of older adults in the U.S. struggle with obesity, with a concerning 34.4% of these individuals also experiencing sarcopenic obesity. This condition puts elderly patients at risk when taking GLP-1 medications designed for weight loss, leading to further muscle reduction and associated complications like frailty and mobility issues. It's crucial to address this dual burden effectively.
The Importance of Muscle Preservation
Enobosarm is designed to offer a critical solution by augmenting fat loss while preserving lean muscle mass. Its effectiveness is particularly relevant for patients undergoing treatments like semaglutide. The Phase 2b study will measure total lean body mass, total body fat mass, and physical function with robust assessments, including a stair climb test at the 16-week mark.
Building upon Previous Research
Previous trials involving enobosarm have shown promise, indicating its ability to increase muscle mass and enhance physical function while reducing fat mass. This research will further validate enobosarm’s role in optimizing weight management, particularly for a vulnerable demographic.
Looking Ahead: The Future of Enobosarm
The company intends to enable participants in this trial to transition into an extension study aimed at ensuring the sustained benefits of enobosarm even after the discontinuation of GLP-1 RA. Anticipation surrounds the topline results, which are expected in early 2025, providing further insights into enobosarm's therapeutic potential.
Veru Inc.'s Commitment to Research and Development
Veru remains steadfast in its mission to equip healthcare providers with advanced treatments for metabolic diseases and related struggles. Its development initiatives include not only enobosarm but also other innovative solutions like sabizabulin, reflecting their comprehensive commitment to healthcare advancement.
Engaging the Community
Through such presentations and ongoing clinical trials, Veru Inc. aims to inform the medical community about the significance of sustaining muscle mass in elderly patients embarking on weight loss journeys. These efforts are vital for enhancing patients’ quality of life and independence.
Investor Relations Contact
Samuel Fisch, the Executive Director of Investor Relations and Corporate Communications, is available for inquiries. Interested parties can reach out via email at veruinvestor@verupharma.com for more detailed information regarding the company's initiatives and future endeavors.
Frequently Asked Questions
What is the main purpose of Veru's presentation at ObesityWeek?
Veru aims to showcase the potential of enobosarm in optimizing weight loss while preserving muscle mass based on data from previous clinical trials.
How does enobosarm work?
Enobosarm is a selective androgen receptor modulator that helps in increasing muscle mass and reducing fat mass, particularly beneficial for older adults with obesity or sarcopenic obesity.
What is sarcopenic obesity?
Sarcopenic obesity refers to the simultaneous presence of obesity and muscle loss, a condition that affects many older adults, making weight management even more challenging.
What are the expected outcomes of the Phase 2b clinical trial?
The trial aims to measure total lean body mass and evaluate whether enobosarm can maintain muscle mass and aid in fat loss during and after GLP-1 RA treatment.
Who can participate in the ongoing clinical trials?
The trials are primarily targeted toward older patients over 60 who are experiencing sarcopenic obesity and are receiving treatment with semaglutide.
